乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) | 80003-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 嘧啶二氮卓类
• 中文名称: 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI)
• 中文别名: 2-氨基-4-氧代-6-乙酰基-7,8-二氢-3H,9H-嘧啶并二氮杂卓
• 英文名称: 6-acetylhomopterin
• 英文别名: 2-Amino-4-oxo-6-acetyl-7,8-dihydro-3H,9H-pyrimidodiazepine；6-acetyl-2-amino-3,7,8,9-tetrahydropyrimido[4,5-b][1,4]diazepin-4-one
• CAS: 80003-63-0
• 化学式: C₉H₁₁N₅O₂
• 分子量: 221.219
• InChiKey: XEAAIJWYCBLWNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7,8-二氢蝶呤 、 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) 生成 Isodrosopterin
  参考文献：
  名称：

  PATON, D. R.;BROWN, G. M., CHEM. AND BIOL. PTERIDINES, 1986. PTERIDINES AND FOLIC ACID DERIV. PROC. +

  摘要：

  DOI：
• 作为产物：
  描述：

  2-amino-6-(4,4-diethoxy-3-oxopentylamino)-5-nitropyrimidin-4(3H)-one 在 sodium dithionite 、 barium(II) chloride 作用下， 生成 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI)
  参考文献：
  名称：

  合成6-乙酰基opter蝶呤。天然存在的嘧啶基[4,5-b] [1,4]二氮杂pine

  摘要：

  2-氨基-4-氧代-6-乙酰基-3,4,7,8-四氢-3H，9H-嘧啶-[4,5-b] [1,4]二氮杂卓（或6-乙酰基acetyl蝶呤）由1-氨基-4,4-二乙氧基-3-戊醇和2-氨基-4-氯-5-硝基-6（1H）-嘧啶酮合成。

  DOI：

  10.1016/s0040-4039(00)96722-4

文献信息

• Pteridines. Part C. Structure and nonenzymatic synthesis of aurodrosopterin
  作者：Jeongbin Yim、Sujeong Kim、Gunter Walcher、Wolfgang Pfleiderer

  DOI：10.1002/hlca.19930760516

  日期：1993.8.11

  The nonenzymatic synthesis of aurodrosopterin (5) from 6-acetyl-2-amino-3, 7, 8, 9-tetrahydro-4H-pyrimido-[4,5-b][1,4]diazepin-4-one (3) and 7,8-dihydrolumazine (4) at pH 3 (HCl) was performed. The identity of the synthesized compound with the natural eye pigment isolated from drosophila heads was confirmed by thin-layer chromatography on cellulose and by comparisons of the 1H-NMR and UV/VIS spectra

  aurodrosopterin（的非酶合成5）由6-乙酰基-2-氨基-3-，7，8，9四氢-4- ħ -pyrimido- [4,5- b ] [1,4]二氮杂-4-酮（3）和在pH 3（HCl）下进行7,8-二氢鲁嗪（4）。通过在纤维素上的薄层色谱法以及通过1 H-NMR和UV / VIS光谱的比较，证实了合成的化合物与从果蝇头部分离出的天然眼色素的身份。由3的非酶促合成新蝶呤类红色素也进行了2，4-二氨基-7，8-二氢蝶啶，但不能确定其身份。这种色素被称为氨基drosopterin，在489 nm处有一个吸收峰，与新drosopterin的吸收峰非常接近。
• Identification and characteristics of the structural gene for the <i>Drosophila</i> eye colour mutant <i>sepia</i>, encoding PDA synthase, a member of the Omega class glutathione S-transferases
  作者：Jaekwang Kim、Hyunsuk Suh、Songhee Kim、Kiyoung Kim、Chiyoung Ahn、Jeongbin Yim

  DOI：10.1042/bj20060424

  日期：2006.9.15

  The eye colour mutant sepia (se1) is defective in PDA 6-acetyl-2-amino-3,7,8,9-tetrahydro-4H-pyrimido[4,5-b]-[1,4]diazepin-4-one or pyrimidodiazepine} synthase involved in the conversion of 6-PTP (2-amino-4-oxo-6-pyruvoyl-5,6,7,8-tetrahydropteridine; also known as 6-pyruvoyltetrahydropterin) into PDA, a key intermediate in drosopterin biosynthesis. However, the identity of the gene encoding this enzyme, as well as its molecular properties, have not yet been established. Here, we identify and characterize the gene encoding PDA synthase and show that it is the structural gene for sepia. Based on previously reported information [Wiederrecht, Paton and Brown (1984) J. Biol. Chem. 259, 2195–2200; Wiederrecht and Brown (1984) J. Biol. Chem. 259, 14121–14127; Andres (1945) Drosoph. Inf. Serv. 19, 45; Ingham, Pinchin, Howard and Ish-Horowicz (1985) Genetics 111, 463–486; Howard, Ingham and Rushlow (1988) Genes Dev. 2, 1037–1046], we isolated five candidate genes predicted to encode GSTs (glutathione S-transferases) from the presumed sepia locus (region 66D5 on chromosome 3L). All cloned and expressed candidates exhibited relatively high thiol transferase and dehydroascorbate reductase activities and low activity towards 1-chloro-2,4-dinitrobenzene, characteristic of Omega class GSTs, whereas only CG6781 catalysed the synthesis of PDA in vitro. The molecular mass of recombinant CG6781 was estimated to be 28 kDa by SDS/PAGE and 56 kDa by gel filtration, indicating that it is a homodimer under native conditions. Sequencing of the genomic region spanning CG6781 revealed that the se1 allele has a frameshift mutation from ‘AAGAA’ to ‘GTG’ at nt 190–194, and that this generates a premature stop codon. Expression of the CG6781 open reading frame in an se1 background rescued the eye colour defect as well as PDA synthase activity and drosopterins content. The extent of rescue was dependent on the dosage of transgenic CG6781. In conclusion, we have discovered a new catalytic activity for an Omega class GST and that CG6781 is the structural gene for sepia which encodes PDA synthase.

  眼色突变体sepia（se1）存在 PDA 6-乙酰基-2-氨基-3,7,8,9-四氢-4H-嘧啶并[4,5-b]-[1,4]二氮杂卓-4-酮或嘧啶二氮杂卓}合成酶缺陷，参与 6-PTP（2-氨基-4-氧代-6-丙酮酰-5,6,7,8-四氢蝶啶；又称 6-丙酮酰四氢蝶啶）转化为 PDA，PDA 是屈蝶呤生物合成过程中的一个关键中间体。然而，编码这种酶的基因及其分子特性尚未确定。在此，我们鉴定了编码 PDA 合成酶的基因并确定了其特性，结果表明它是萼片的结构基因。根据以前报告的信息 [Wiederrecht, Paton and Brown (1984) J. Biol.Chem.259, 2195-2200; Wiederrecht and Brown (1984) J. Biol.Chem.259, 14121-14127; Andres (1945) Drosoph.Inf.Serv。19, 45; Ingham, Pinchin, Howard and Ish-Horowicz (1985) Genetics 111, 463-486; Howard, Ingham and Rushlow (1988) Genes Dev.2，1037-1046]，我们从假定的 sepia 基因座（3L 染色体上的 66D5 区域）分离出了五个预测编码 GST（谷胱甘肽 S-转移酶）的候选基因。所有克隆和表达的候选基因都表现出较高的硫醇转移酶和脱氢抗坏血酸还原酶活性，而对 1-氯-2,4-二硝基苯的活性较低，这是 Omega 类 GST 的特征，而只有 CG6781 在体外催化了 PDA 的合成。重组 CG6781 的分子质量经 SDS/PAGE 测定为 28 kDa，经凝胶过滤测定为 56 kDa，表明它在原生条件下是一个同源二聚体。对横跨 CG6781 的基因组区域进行测序后发现，se1 等位基因在 nt 190-194 处发生了从 "AAGAA "到 "GTG "的移帧突变，从而产生了一个过早的终止密码子。在se1背景下表达CG6781开放阅读框可以挽救眼睛颜色缺陷以及PDA合成酶活性和屈螺酮含量。挽救的程度取决于转基因 CG6781 的剂量。总之，我们发现了一种新的Ω类 GST 催化活性，CG6781 是编码 PDA 合成酶的 sepia 结构基因。
• Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
  申请人：UNIVERSIDAD DE LA HABANA

  公开号：US10722491B2

  公开（公告）日：2020-07-28

  The present invention relates to Chemistry, Pharmaceutical and in particular to the preparation of formulations from derivatives of phenolic or polyphenolic compounds and from derivatives of phenolic or polyphenolic compounds combined with tricyclic systems of the benzodiazepine type fused to derivatives of 1,4-dihydropyridines with action on the Central Nervous and Vascular Systems. These pharmaceutical compositions exhibit GABAergic, antiglutamatergic, calcium channel modulating, mitoprotective, anti-oxidant, anti-inflammatory, and antiapoptotic action, usable in the treatment of cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric and neurological diseases.

  本发明涉及化学、制药领域，特别是涉及苯酚或聚苯酚衍生物以及与苯二氮卓类三环系统结合的苯酚或聚苯酚衍生物的制剂制备，所述苯二氮卓类三环系统与具有作用于中枢神经系统和血管系统的1,4-二氢吡啶衍生物融合。这些 pharmaceutical compositions展示GABA样、抗谷氨酸、钙通道调节、线粒体保护、抗氧化、抗炎和抗凋亡作用，可用于治疗心血管、脑血管、神经退行性疾病、神经精神疾病和神经疾病。
• Boyle, Peter H.; Hughes, Enid M.; Khattab, Hassan A., Journal of the Chemical Society. Perkin transactions I, 1990, # 7, p. 2071 - 2077
  作者：Boyle, Peter H.、Hughes, Enid M.、Khattab, Hassan A.、Lockhart, Ronan J.

  DOI：——

  日期：——
• BOYLE, PETER H.;HUGHES, ENID M.;KHATTAB, HASSAN A.;LOCKHART, RONAN J., TETRAHEDRON LETT., 28,(1987) N 44, 5331-5334
  作者：BOYLE, PETER H.、HUGHES, ENID M.、KHATTAB, HASSAN A.、LOCKHART, RONAN J.

  DOI：——

  日期：——